

164. Tang BH, Wu YE, Kou C, et al. Population pharmacokinetics and dosing optimization of amoxicillin in neonates and young infants. *Antimicrob Agents Chemother* 2019;63:e02336-18. PMID:30509939 <https://doi.org/10.1128/AAC.02336-18>
165. Thanaviratananich S, Laopaiboon M, Vatanasapt P. Once or twice daily versus three times daily amoxicillin with or without clavulanate for the treatment of acute otitis media. *Cochrane Database Syst Rev* 2013;(12):CD004975. PMID:24338106 <https://doi.org/10.1002/14651858.CD004975.pub3>
166. Tremoulet A, Le J, Poindexter B, et al.; Administrative Core Committee of the Best Pharmaceuticals for Children Act-Pediatric Trials Network. Characterization of the population pharmacokinetics of ampicillin in neonates using an opportunistic study design. *Antimicrob Agents Chemother* 2014;58:3013–20. PMID:24614374 <https://doi.org/10.1128/AAC.02374-13>
167. Watt KM, Massaro MM, Smith B, Cohen-Wolkowicz M, Benjamin DK Jr, Laughon MM. Pharmacokinetics of moxifloxacin in an infant with *Mycoplasma hominis* meningitis. *Pediatr Infect Dis J* 2012;31:197–9. PMID:22016080 <https://doi.org/10.1097/INF.0b013e31823980c3>
168. Wildenbeest JG, Said I, Jaeger B, van Hest RM, van de Beek D, Pajkrt D. Neonate with *Mycoplasma hominis* meningoencephalitis given moxifloxacin. *Lancet Infect Dis* 2016;16:e261–6. PMID:27641775 [https://doi.org/10.1016/S1473-3099\(16\)30162-1](https://doi.org/10.1016/S1473-3099(16)30162-1)
169. Yoshizawa K, Ikawa K, Ikeda K, Ohge H, Morikawa N. Population pharmacokinetic-pharmacodynamic target attainment analysis of imipenem plasma and urine data in neonates and children. *Pediatr Infect Dis J* 2013;32:1208–16. PMID:23676856 <https://doi.org/10.1097/INF.0b013e31829b5880>
170. Zhanel GG, Esquivel J, Zelenitsky S, et al. Omadacycline: a novel oral and intravenous aminomethylcycline antibiotic agent. *Drugs* 2020;80:285–313. PMID:31970713 <https://doi.org/10.1007/s40265-020-01257-4>
171. Zhao W, Hill H, Le Guellec C, et al.; TINN Consortium. Population pharmacokinetics of ciprofloxacin in neonates and young infants less than three months of age. *Antimicrob Agents Chemother* 2014;58:6572–80. PMID:25155587 <https://doi.org/10.1128/AAC.03568-14>
172. Occupational Safety and Health Administration. Anthrax: control and prevention. Washington, DC: US Department of Labor, Occupational Safety and Health Administration. https://www.osha.gov/anthrax/control-prevention#specific_work
173. Swartz MN. Recognition and management of anthrax—an update. *N Engl J Med* 2001;345:1621–6. PMID:11704686 <https://doi.org/10.1056/NEJMra012892>